Literature DB >> 21948167

Preclinical chemotherapeutic tumor models of common childhood cancers: solid tumors, acute lymphoblastic leukemia, and disseminated neuroblastoma.

Christopher L Morton1, Rachel A Papa, Richard B Lock, Peter J Houghton.   

Abstract

This unit presents three models used in the Pediatric Preclinical Testing Program of the National Cancer Institute (NCI) for preclinical testing of new chemical entities (NCEs), along with appropriate methods for data analysis. The first is the classical subcutaneous xenograft model used for many solid tumors, the second is the disseminated human leukemia model established by Lock and colleagues, and the third is a disseminated model of neuroblastoma that recapitulates many of the characteristics of advanced clinical disease.
© 2007 by John Wiley & Sons, Inc.

Entities:  

Mesh:

Year:  2007        PMID: 21948167     DOI: 10.1002/0471141755.ph1408s39

Source DB:  PubMed          Journal:  Curr Protoc Pharmacol        ISSN: 1934-8282


  8 in total

Review 1.  Patient-Derived Xenografts as a Model System for Radiation Research.

Authors:  Christopher D Willey; Ashley N Gilbert; Joshua C Anderson; George Yancey Gillespie
Journal:  Semin Radiat Oncol       Date:  2015-05-14       Impact factor: 5.934

2.  Evaluation of Alternative In Vivo Drug Screening Methodology: A Single Mouse Analysis.

Authors:  Brendan Murphy; Han Yin; John M Maris; E Anders Kolb; Richard Gorlick; C Patrick Reynolds; Min H Kang; Stephen T Keir; Raushan T Kurmasheva; Igor Dvorchik; Jianrong Wu; Catherine A Billups; Nana Boateng; Malcolm A Smith; Richard B Lock; Peter J Houghton
Journal:  Cancer Res       Date:  2016-08-05       Impact factor: 12.701

3.  Targeting Histone Demethylases in MYC-Driven Neuroblastomas with Ciclopirox.

Authors:  Jun Yang; Sandra Milasta; Dongli Hu; Alaa M AlTahan; Rodrigo B Interiano; Junfang Zhou; Jesse Davidson; Jonathan Low; Wenwei Lin; Ju Bao; Pollyanna Goh; Amit C Nathwani; Ruoning Wang; Yingdi Wang; Su Sien Ong; Vincent A Boyd; Brandon Young; Sourav Das; Anang Shelat; Yinan Wu; Zhenmei Li; Jie J Zheng; Ashutosh Mishra; Yong Cheng; Chunxu Qu; Junmin Peng; Douglas R Green; Stephen White; R Kiplin Guy; Taosheng Chen; Andrew M Davidoff
Journal:  Cancer Res       Date:  2017-07-06       Impact factor: 12.701

4.  Establishment and characterization of the first pediatric adrenocortical carcinoma xenograft model identifies topotecan as a potential chemotherapeutic agent.

Authors:  Emilia M Pinto; Christopher Morton; Carlos Rodriguez-Galindo; Lisa McGregor; Andrew M Davidoff; Kimberly Mercer; Larisa V Debelenko; Catherine Billups; Raul C Ribeiro; Gerard P Zambetti
Journal:  Clin Cancer Res       Date:  2013-02-13       Impact factor: 12.531

5.  Pediatric high grade glioma: a review and update on tumor clinical characteristics and biology.

Authors:  Jason Fangusaro
Journal:  Front Oncol       Date:  2012-08-24       Impact factor: 6.244

6.  BET inhibitors induce apoptosis through a MYC independent mechanism and synergise with CDK inhibitors to kill osteosarcoma cells.

Authors:  Emma K Baker; Scott Taylor; Ankita Gupte; Phillip P Sharp; Mannu Walia; Nicole C Walsh; Andrew Cw Zannettino; Alistair M Chalk; Christopher J Burns; Carl R Walkley
Journal:  Sci Rep       Date:  2015-05-06       Impact factor: 4.379

7.  Regulated lysosomal exocytosis mediates cancer progression.

Authors:  Eda Machado; Shai White-Gilbertson; Diantha van de Vlekkert; Laura Janke; Simon Moshiach; Yvan Campos; David Finkelstein; Elida Gomero; Rosario Mosca; Xiaohui Qiu; Christopher L Morton; Ida Annunziata; Alessandra d'Azzo
Journal:  Sci Adv       Date:  2015-12-18       Impact factor: 14.136

8.  Forty-five patient-derived xenografts capture the clinical and biological heterogeneity of Wilms tumor.

Authors:  Andrew J Murphy; Xiang Chen; Emilia M Pinto; Justin S Williams; Michael R Clay; Stanley B Pounds; Xueyuan Cao; Lei Shi; Tong Lin; Geoffrey Neale; Christopher L Morton; Mary A Woolard; Heather L Mulder; Hyea Jin Gil; Jerold E Rehg; Catherine A Billups; Matthew L Harlow; Jeffrey S Dome; Peter J Houghton; John Easton; Jinghui Zhang; Rani E George; Gerard P Zambetti; Andrew M Davidoff
Journal:  Nat Commun       Date:  2019-12-20       Impact factor: 14.919

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.